RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
February 23, 2017 The Life Sciences Report RXi Pharmaceuticals’ proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It’s no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In […]
RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology Read More »